Family 18: Transcriptional and Nuclear Signalling
Family overview. Transcription factors and nuclear receptors — NF-κB, Nrf2, STAT proteins, nuclear hormone receptors — integrate cellular stress signals into coordinated gene expression responses. Their chronic dysregulation underlies most features of chronic inflammatory disease.
Concrete mechanisms and ME/CFS evidence:
NF-κB pathway. Chronically elevated pro-inflammatory cytokines (Family 4) require sustained NF-κB activity for their transcription; nuclear NF-κB has not been directly quantified in ME/CFS cells, but downstream cytokine data provides strong indirect evidence.
Nrf2 antioxidant response. Nrf2 normally orchestrates antioxidant gene expression (glutathione synthesis, SOD, catalase) in response to oxidative stress; impaired Nrf2 activation would explain inadequate antioxidant response despite persistent ROS elevation. Direct Nrf2 nuclear translocation data in ME/CFS is very sparse.
STAT1/STAT3 dysregulation. Altered type I interferon signalling implies STAT1 pathway dysregulation; STAT3 involvement in IL-6 signalling and immune cell differentiation is plausible given the cytokine profile.
Vitamin D receptor (VDR) blockade. EBV EBNA-3 blocks VDR-dependent gene activation (see Family 16), impairing the vitamin D nuclear receptor pathway’s role in immune regulation.
Glucocorticoid receptor sensitivity loss. Epigenetic reduction in glucocorticoid receptor (GR) sensitivity impairs HPA axis negative feedback and glucocorticoid-mediated anti-inflammatory signalling (Roberts et al. 2017).
Thyroid hormone nuclear receptor hypoactivation. Low T3 syndrome implies reduced thyroid hormone receptor (TR) activation in target tissues despite normal systemic T4; functional tissue-level hypothyroidism in the absence of gland pathology.
Evidence status: Theoretical (mostly inferred from downstream effectors; direct transcription factor assays in ME/CFS remain rare; mechanistically coherent with documented findings).
Nrf2 and NF-κB are reciprocally regulated: Nrf2 activation suppresses NF-κB, while NF-κB activity suppresses Nrf2. Under normal physiology, oxidative stress activates Nrf2 first (protective antioxidant response); only when Nrf2 is overwhelmed does NF-κB dominate (inflammatory response). Three independent lines of ME/CFS evidence suggest all three major transcriptional brakes on NF-κB are simultaneously impaired:
- Glucocorticoid receptor (GR) hyposensitivity. Epigenetically reduced GR sensitivity (Family 12) impairs glucocorticoid-mediated NF-κB suppression (Roberts et al. 2017).
- Vitamin D receptor (VDR) blockade. EBV EBNA-3 protein competitively inhibits VDR-dependent gene activation (Family 16), removing vitamin D’s anti-inflammatory brake on NF-κB.
- Nrf2 impairment (hypothetical). If chronic oxidative stress exhausts or epigenetically suppresses Nrf2 nuclear translocation, the third NF-κB brake is also released.
If all three brakes fail simultaneously, NF-κB activity is constitutively elevated without any endogenous checkpoint capable of resolving it — explaining the self-sustaining chronic inflammation observed in ME/CFS despite the absence of ongoing acute infection. This hypothesis would move Family 18 from “theoretical” to “emerging” with a single targeted assay measuring Nrf2, GR, and VDR nuclear translocation in patient PBMCs.
Certainty: 0.35. GR and VDR components have direct evidence; Nrf2 component is inferred. Not yet tested as a unified three-factor mechanism.